Previous 10 | Next 10 |
The following slide deck was published by Mylan N.V. in conjunction with their 2019 Q3 earnings Read more ...
Image source: The Motley Fool. Mylan N.V. (NASDAQ: MYL) Q3 2019 Earnings Call Nov 5, 2019 , 10:00 a.m. ET Operator Continue reading
Mylan (NASDAQ: MYL ): Q3 Non-GAAP EPS of $1.17 beats by $0.03 ; GAAP EPS of $0.37 misses by $0.11 . Revenue of $2.96B (+3.5% Y/Y) misses by $50M . Shares +1.6% PM. Press Release More news on: Mylan N.V., Earnings news and commentary, Stocks on the move, Healthcare stocks news,...
HERTFORDSHIRE, England and PITTSBURGH , Nov. 5, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three and nine months ended September 30, 2019. Third Quarter 2019 Financial Highlights U.S. GAAP diluted earnings per ordinary ...
In a statement , the FDA says chronic shortages of certain medicines in the U.S. have not produced the expected responses from drugmakers that traditional economics predict, specifically, increasing prices to reflect a supply/demand imbalance aimed at achieving profitable production to sati...
Insurance company versus big pharma - whose money is it anyway? Humana Inc. (HUM), a $39 billion health insurance company, accuses Teva Pharmaceutical Industries (TEVA), an $8 billion company, and a few other generic drug makers, of playing ugly in the generic drugs market. In a 610-page c...
NESS ZIONA, Israel, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd . announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS). Glatiramer acetate, the active material of Copaxone®, or its generic...
MORGANTOWN, W.Va. , Oct. 25, 2019 /PRNewswire/ -- Mylan Pharmaceuticals Inc. is conducting a voluntary nationwide recall of one lot (see table below) of Alprazolam Tablets, USP C-IV 0.5 mg, to the consumer/user level. This lot is being recalled due to the potential presence of foreig...
HERTFORDSHIRE, England and PITTSBURGH , Oct. 24, 2019 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its third quarter 2019 financial results on Tuesday, Nov. 5 before the open of the U.S. financial markets. The co...
The opioid epidemic is a complex problem with no simple or ideal solution. The Centers for Disease Control and Prevention (CDC) estimates that 47,600 Americans died from opioid-related overdoses in 2017. One study published earlier this year by Massachusetts General Hospital estimates that 700,0...
News, Short Squeeze, Breakout and More Instantly...
Mylan Announces Third Quarter 2020 Financial Results and Looks Ahead to the Launch of Viatris Inc. PR Newswire HERTFORDSHIRE, England and PITTSBURGH, Nov. 6, 2020 HERTFORDSHIRE, England and PITTSBURGH , Nov. 6, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ...
Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more. A long-awaited deal will soon be done. Pfizer (NYSE: PFE) and Mylan (NASDAQ: MYL) announced last week that the U.S. Federal Trade Commission has approved the planned merger of Pfizer's...
Mylan Announces Appointment of Experienced Pharmaceutical Executive Bill Szablewski as Head of Capital Markets for Viatris PR Newswire HERTFORDSHIRE, England, and PITTSBURGH, Nov. 2, 2020 HERTFORDSHIRE , England, and PITTSBURGH, Nov. 2, 2020 /PRNews...